Skip to main content
. 2024 Jan 27;20(4):1279–1296. doi: 10.7150/ijbs.89700

Figure 1.

Figure 1

CSN5 inhibition sensitizes EOC to platinum in vitro and in vivo and induces apoptosis in platinum-resistant EOC cells. (A, D) DDP cells with or without CSN5 inhibition, genetically or pharmacologically, were exposed to cisplatin or not for 24 h (CSN5i-3, 5 μM; Cisplatin, 20 μM, A2780DDP; 10 μM, SKOV3DDP). The proliferation effects were assessed by colony formation assay. (B, C, E, F) DDP cells with or without CSN5 inhibition were treated with different doses of cisplatin for 24 h, and the cellular viability was evaluated by CCK-8 assay. (G) An in vivo xenograft model was employed to show the anti-tumor effects of CSN5 inhibition (Cisplatin, 5 mg/kg i.p). (H, I) Tumor weight and volume were analyzed. (J) Annexin V-FITC/7-AAD staining was employed to test the cellular apoptosis of DDP cells with or without CSN5 inhibition. (K-N) Flow cytometry was used to detect and quantify the cellular apoptotic levels.